Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visterra hooks Pfizer with pan-influenza anti-HA MAb

This article was originally published in Scrip

Executive Summary

Cambridge, Massachusetts-based Visterra isn't exactly a startup, since that has already raised over $22 million in seed and venture capital since its foundation in 2007. But the small biotechnology firm is coming out of stealth mode with its first Big Pharma partnership - with Pfizer - and the presentation of preclinical data for VIS410, its fully human monoclonal antibody against influenza, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) from 9 to 12 September in San Francisco.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel